RxDoctor Payments Data

Saima Jalal, MD

Ophthalmology · St Charles, ILNPI 1962599829

Payments from drug & device makers

$2,346in general payments, 2019–2025

Across 79 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$390
  • Alcon$378
  • Regeneron Healthcare Solutions, Inc.$236
  • Sight Sciences, Inc.$196
  • Carl Zeiss Meditec, Inc.$178
  • Rxsight Inc$178
  • plus $792 from 16 others

What the payments were for

  • Food & beverage$2,26797%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,346 in reported general payments places this provider in the 60th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,074,916
Medicare patients
803
Services billed
13,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$35,971
XiidraLifitegrast16$23,522
LumiganBimatoprost12$8,506
Latanoprost394$7,418
Dorzolamide-TimololDorzolamide/Timolol/Pf43$6,820
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat229$3,314
Timolol Maleate151$2,567
Brimonidine Tartrate58$2,336
Doxycycline Hyclate57$2,320
Prednisolone Acetate43$1,626
Ketorolac Tromethamine36$765
Dorzolamide Hcl21$376
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha40$343
Ofloxacin14$160
Tobramycin15$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$390$44,47640 claims
Bausch & Lomb Americas Inc.Xiidra$19$23,52216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in St Charles

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →